Vaccine News and Research

Latest Vaccine News and Research

Oncothyreon prices underwritten public offering of common stock

Oncothyreon Inc. today announced that it has priced an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $4.00 per share for gross proceeds of $40.0 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by Oncothyreon, will be approximately $37.4 million.

29 Apr 2011

Flu vaccination lowers kidney transplant recipients' risk of organ loss and death

Getting vaccinated against the flu lowers kidney transplant recipients' risk of organ loss and death, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

29 Apr 2011

Portuguese researcher to earn Bill & Melinda Gates Foundation award for new HIV therapy

João Gonçalves, from Faculdade de Farmácia e Instituto de Medicina Molecular, Lisbon, Portugal, to win a Grand Challenges Exploration Award

29 Apr 2011

Study finds low pediatric flu vaccination acceptance rates in Atlanta

A study of H1N1 and seasonal influenza vaccination in a sample of black and Hispanic children in Atlanta found a low rate of vaccine acceptance among parents and caregivers.

29 Apr 2011

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.

28 Apr 2011

Nautic Partners announces acquisition of Omnicare Clinical Research

Nautic Partners LLC, a private equity firm with more than $2.5 billion of capital under management, today announced that it has acquired Omnicare Clinical Research from Omnicare, Inc. Headquartered in King of Prussia, PA, Omnicare CR is a full-service, global clinical research organization.

28 Apr 2011

Seattle BioMed study to identify biomarkers for malaria vaccine design

In the first study of its type in the malaria field, Seattle BioMed has been awarded an $8.9 million grant from the Bill & Melinda Gates Foundation to identify biomarkers that will allow malaria vaccine design based on robust predictors of protective immunity.

28 Apr 2011

NIH awards UH with $361,000 grant for chikungunya vaccine study

It is spread to humans by mosquito bites, causing arthritic symptoms so severe that some victims can't even walk. While rarely fatal, the effects of the chikungunya virus can last up to a year.

28 Apr 2011

Rwanda launches Africa's first nationwide cervical cancer vaccination, detection program

Rwandan First Lady Jeannette Kagame on Tuesday, in collaboration with two companies, launched a national cervical cancer vaccination and screening program, the first of its kind in Africa, the New Times reports.

27 Apr 2011

EPO grants patent to Microbix' VIRUSMAX vaccine enhancement technology

Microbix Biosystems Inc., a biotechnology company commercializing novel technologies to enhance vaccine production yields, and other innovative biologics, announced today that the European Patent Office recently granted patent protection for the company's proprietary VIRUSMAX technology, which is designed to increase influenza vaccine yields and has demonstrated an average yield increase of at least two-fold over current vaccine production methods.

27 Apr 2011

Researchers develop protein-based inhibitor that can treat HPV

Human papillomavirus causes cervical cancer, the second most common cause of cancer death for women, and is a common cause of anogenital and some head and neck cancers.

27 Apr 2011

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

Vertex pharmaceuticals jumped 10 percent in value on the Nasdaq after U.S. regulators FDA said the company’s experimental hepatitis C drug cures more patients than current therapies.

26 Apr 2011

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.

26 Apr 2011

Caliber opens world's largest plant-made pharmaceutical facility in Bryan

Caliber Biotherapeutics, a fully-integrated biopharmaceutical company, announced the opening of the world's largest plant-made pharmaceutical manufacturing facility in Bryan, Texas, with the capability of producing 10-100 million doses of infectious vaccines per month, and hundreds of thousands of doses of protein biotherapeutics such as monoclonal antibodies.

26 Apr 2011

Aquilent launches new vaccine government site to help citizens stay healthy

Aquilent, the recognized leading provider of Web-based solutions shaping the next generation of technology for the federal government, today announced its development support role in the newly launched Vaccines.gov site, under contract with the U.S. Department of Health and Human Services.

26 Apr 2011

NovaSterilis novel vaccine patent

NovaSterilis Inc., a leader in the development and commercialization of supercritical carbon dioxide technology, has been granted US Patent 7,919,096. The patent, dated April 5th 2011, is entitled “Inactivating Organisms Using Carbon Dioxide At or Near Supercritical Pressure and Temperature Conditions.”

25 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

New study reports national survey results of physicians who deliver childhood vaccinations

A new study led by Allison Kempe, MD, MPH, professor of Pediatrics at the University of Colorado School of Medicine and director of the Children's Outcomes Research Program at The Children's Hospital, reports the results of a national survey of primary care physicians who deliver vaccinations to children.

25 Apr 2011

Ahead of Immunization Week, WHO calls for countries to come together to control measles outbreak in Europe

WHO is urging countries in Europe to join together to help control the measles outbreak that has grown to more than 6,500 cases in 33 countries and the potential for worsening outbreaks "in the days ahead as people travel during the Easter holidays," U.N. News Centre reports.

25 Apr 2011

Canadians join hands in fight against meningitis on April 24th

Canadians can join hands in a virtual community with the Meningitis Research Foundation of Canada and become a member of the global family by visiting www.comoonline.org and "joining hands" in the fight against meningitis, and to show support for meningitis awareness and prevention.

25 Apr 2011